CD22 and diffuse large B-cell lymphoma: In a clinical trial of adults with r/r DLBCL, we tested unique loop-structured CD19/CD22 BS Loop CAR-T cells and demonstrated their outstanding clinical efficacy (80% CR) and well-tolerated toxicity in r/r DLBCL patients.